Case report reveals interference in oestradiol assays in breast cancer patients treated with abemaciclib, indicating clinical implications.
Background: Abemaciclib is a CDK4/6 inhibitor used in breast cancer treatment alongside endocrine therapy. Positive interference in the Abbott Alinity (AA) oestradiol assay in premenopausal woman receiving abemaciclib, despite ovarian function suppression, was shown using liquid chromatography-mass spectrometry (LC-MS/MS). 1,2 We investigated a patient with abemaciclib interference using several oestradiol assays.
No takes yet. Share an insight, caveat, or question.
Chan et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: